Skip to content
Peptide research

Vladonix

Also known as Thymus Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

What it is

A bovine thymus-derived peptide marketed to restore immune competence and slow age-related thymic decline. The case rests mostly on mechanism and animal data; human evidence is low-confidence, and claims of post-chemo recovery or lower mortality with long-term use are speculative. Chief risk is immune overstimulation in autoimmune conditions, plus low risks of allergy and prion exposure. Not FDA-approved; sold mainly as unregulated products online.

Read Full record

Studied uses & evidence

Studied uses(4)

  • Immune system restoration and normalization

    Low

    Based mainly on injectable Thymalin data, not oral Vladonix, with unblinded, preliminary human reporting.

  • Post-radiation/chemotherapy immune recovery

    Speculative

    Indirect evidence from a Vilon colorectal-cancer report indexed as a controlled clinical trial; it does not establish benefit for oral Vladonix.

  • Reduced mortality in long-term anti-aging protocols

    Speculative

    Based on one unreplicated study of injectable peptides, not modern trial design or oral Vladonix.

Evidence limits

Evidence Level
Limited Evidence (with stronger data for related injectable Thymalin)

Direct evidence for Vladonix capsules is limited to Khavinson Institute reports. However, the related injectable Thymalin has decades of Russian clinical use and the most extensive published data of any Khavinson peptide, including the landmark Kiev study showing mortality reduction over 6-12 years. The PMC-indexed thymalin review (PMC8365293) provides robust molecular mechanism data. Vladonix oral capsules are extrapolated from this stronger evidence base.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Allergic reaction to bovine thymus-derived peptides

    Low
  • Potential immune overstimulation in autoimmune conditions

    Moderate
  • Prion/BSE concerns (bovine thymus origin)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.